Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Authors
Keywords
Immunotherapy, Cancer, ICU, Adverse events
Journal
Annals of Intensive Care
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-01
DOI
10.1186/s13613-019-0487-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists
- (2018) Mauro Frigeri et al. CANADIAN JOURNAL OF CARDIOLOGY
- Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer
- (2018) Yuichiro Yasuda et al. INTERNAL MEDICINE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- (2018) Eleonora De Martin et al. JOURNAL OF HEPATOLOGY
- Severe neurologic complications of immune checkpoint inhibitors: a single-center review
- (2018) Sarah Mancone et al. JOURNAL OF NEUROLOGY
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
- (2018) Aaron Lisberg et al. Cancer Immunology Research
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
- (2018) Irena Tan et al. Journal for ImmunoTherapy of Cancer
- Endocrine side effects of cancer immunotherapy
- (2017) Priscilla Cukier et al. ENDOCRINE-RELATED CANCER
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
- (2017) D. Makarious et al. EUROPEAN JOURNAL OF CANCER
- Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non–small cell lung cancer
- (2017) Linda Mahjoubi et al. EUROPEAN JOURNAL OF CANCER
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Challenges faced when identifying patients for combination immunotherapy
- (2017) Marc S Ernstoff et al. Future Oncology
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Myasthenia triggered by immune checkpoint inhibitors: New case and literature review
- (2017) Natalia L. Gonzalez et al. NEUROMUSCULAR DISORDERS
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
- (2017) Julia Judd et al. ONCOLOGIST
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
- (2017) Justin C. Kao et al. JAMA Neurology
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Cardiovascular Toxicities Associated with Cancer Immunotherapies
- (2017) Daniel Y. Wang et al. Current Cardiology Reports
- Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression
- (2017) Georgina V. Long et al. JAMA Oncology
- Immunotherapy-associated autoimmune hemolytic anemia
- (2017) Uqba Khan et al. Journal for ImmunoTherapy of Cancer
- Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
- (2016) Anushree C. Shirali et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
- (2016) Patrizio Caturegli et al. AMERICAN JOURNAL OF PATHOLOGY
- Myasthenic crisis and polymyositis induced by one dose of nivolumab
- (2016) Toshihiro Kimura et al. CANCER SCIENCE
- Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion
- (2016) Igal Kushnir et al. CARDIOLOGY
- Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
- (2016) Simone M. Goldinger et al. CLINICAL CANCER RESEARCH
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report
- (2016) Magalie P. Tardy et al. HEMATOLOGICAL ONCOLOGY
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
- (2016) Frank B. Cortazar et al. KIDNEY INTERNATIONAL
- Neurological sequelae of cancer immunotherapies and targeted therapies
- (2016) Wolfgang Wick et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
- (2016) Tanya J. Williams et al. JAMA Neurology
- Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
- (2016) M. Nishino et al. Cancer Immunology Research
- Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
- (2016) J. Naidoo et al. Cancer Immunology Research
- Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma
- (2016) Constantin A Dasanu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Ipilimumab-associated Hepatitis
- (2015) Melanie Johncilla et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- (2015) Juan Martin-Liberal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
- (2015) Giuliana Carlos et al. MELANOMA RESEARCH
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
- (2015) Mizuki Nishino et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Kidney injuries related to ipilimumab
- (2014) Hassane Izzedine et al. INVESTIGATIONAL NEW DRUGS
- Severe acute respiratory distress syndrome due to ipilimumab
- (2013) Daniel Franzen et al. EUROPEAN RESPIRATORY JOURNAL
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Ipilimumab associated hepatitis: imaging and clinicopathologic findings
- (2013) Kyung Won Kim et al. INVESTIGATIONAL NEW DRUGS
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
- (2009) James D. Lord et al. DIGESTIVE DISEASES AND SCIENCES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started